Concepta Share Discussion Threads

[cottoner] 19/8/2016 14:50

very good - all that is available. :-)

[runwaypaul] 19/8/2016 14:49

is that all you can afford?

[cottoner] 19/8/2016 14:45

Currently can buy max of 3000 shares online.

[runwaypaul] 19/8/2016 13:27

when they do pump it in the autumn i may glady dump.Hopefully taking a bag or two with me!

[rubberbullets] 19/8/2016 13:12

Looks a pump and dump


Why no directors listed for Mercia




Information on Christopher Potts another dumper

[affemoose] 19/8/2016 12:41

As with all of these things.....i believe it when it happens :-)

Not being negative just been burnt so many times.

[runwaypaul] 19/8/2016 10:12

hxxps://issuu.com/ukinvestormagazine/docs/august_2016

[runwaypaul] 19/8/2016 10:11

according to interview with ukinvestor will be generating cash within next 2 months,expects a shareprice of 'well north'of 20p by xmas.

[smart_investor] 19/8/2016 07:59

From RNS - Adam Reynolds Outlook


We are delighted to have successfully completed the reverse takeover at the end of this reporting period and are looking forward to an exciting future as Concepta.


The immediate focus following Concepta's RTO in July 2016, is the launch of MyLotus in China later this year (2016) and, subsequent to CE marking, targeting launch in the UK and Europe in 2017. In addition we are looking to set up new manufacturing facilities in Yorkshire, which will be another key milestone in our Company's development. Excitingly, Concepta has the opportunity to translate its proprietary platform into commercial success in these initial markets where annual revenues in the infertility segment are estimated to be worth c.£600m.


Furthermore, Concepta's products have myriad applications beyond fertility diagnostics, and we are in a unique position to come in at the ground floor of the fast growing global connected healthcare sector, which is set to be worth $61bn by 2020.


We look forward to updating the market on these exciting developments during the course of 2016 and beyond as we implement our defined growth strategy, focused on delivering commercial success and becoming the global market leader for over-the counter products for women with fertility issues and, ultimately, tackling the wider mobile health market.


Go to previousSubmit

[smart_investor] 19/8/2016 07:58

From RNS - Adam Reynolds Outlook


We are delighted to have successfully completed the reverse takeover at the end of this reporting period and are looking forward to an exciting future as Concepta.


The immediate focus following Concepta's RTO in July 2016, is the launch of MyLotus in China later this year (2016) and, subsequent to CE marking, targeting launch in the UK and Europe in 2017. In addition we are looking to set up new manufacturing facilities in Yorkshire, which will be another key milestone in our Company's development. Excitingly, Concepta has the opportunity to translate its proprietary platform into commercial success in these initial markets where annual revenues in the infertility segment are estimated to be worth c.£600m.


Furthermore, Concepta's products have myriad applications beyond fertility diagnostics, and we are in a unique position to come in at the ground floor of the fast growing global connected healthcare sector, which is set to be worth $61bn by 2020.


We look forward to updating the market on these exciting developments during the course of 2016 and beyond as we implement our defined growth strategy, focused on delivering commercial success and becoming the global market leader for over-the counter products for women with fertility issues and, ultimately, tackling the wider mobile health market.

[affemoose] 17/8/2016 09:20

Moaning all - back from my hols and this is still fairly stable - i'm happy with that for sure, looking forwards to a slow but steady rise over the next 2 years - which is my timeframe.

[smart_investor] 15/8/2016 13:31

"We are expecting a highly active start to our life on AIM, with the roll out of My Lotus in China set to commence in Q3 2016 and thereafter in the UK and Europe in 2017."

News should be by end of the month or start of next month. We know Concepta are travelling to China during this month as Erik said so on a recent interview.

[cottoner] 15/8/2016 10:45

Just waiting for news, esp wrt China.

[fillipe] 15/8/2016 10:42

This one a bit dead in the water and seemingly of no great interest as far as the product in concerned.

Whatever the future turns out to be, it will need have to be a bit sparky to revive the inital enthusiasm, imo.

f

[luminoso] 12/8/2016 12:26

Interesting, thanks.

[smart_investor] 11/8/2016 22:24

Article published today. More media coverage - I like the last line



In just three years, Concepta Diagnostics Ltd has been able to develop an innovative testing platform, obtain product registration and successfully list on the Alternative Investment Market (AIM).

It is estimated that the global mobile health market will be worth $23bn in 2017(1), and it is growing fast: by 2020 it will be worth $61bn(2). Concepta is a key player in this emerging segment having developed a product that focuses on “unexplained infertility” and helping women who suffer from it to conceive.

In just three years, the company has been able to develop an innovative testing platform, obtain product registration and - following a successful listing on the Alternative Investment Market (AIM) on 26th July - is now ready to start commercialisation.

A substantial minority of women struggle to conceive despite many months of trying. And, if doctors cannot find anything physically wrong, these women are usually faced with lengthy periods of worry, insecurity and anxiety. Because they are not typically offered medical assistance until at least a year of trying for a baby unsuccessfully, and aren’t offered IVF until two years have passed, there is a significant period in which these women may feel they aren’t taking enough proactive steps to conceive.

Concepta’s flagship product, MyLotus, measures common issues that can affect a woman’s probability of conception in any given cycle. These issues can vary from cycle to cycle, and when properly accounted for, can reduce the time taken to conceive whereno cause of infertility has been previously identified. MyLotus provides quantitative as well as qualitative results, which is unique for a home fertility test of this kind.

Excitingly, this is only one of many potential future applications for Concepta’s platform. Pharmaceutical companies could use the technology to more effectively monitor patients administering drugs at home – this would be particularly useful as part of clinical trials or to ensure that dosages can be more finely tailored to individual tolerances and requirements.

Likewise, government healthcare representatives should see the value in using this kind of technology to reduce healthcare reliance and hospital admissions by encouraging better health at home. Indeed, indications suggest that in 2017, mobile health could save a total €99bn in healthcare costs in the EU.(3)

The fundamental issues that the Company’s products address are universal and the consumer proposition is unique. Further, a modular manufacturing set-up means flexibility for future applications. Britain’s vote to leave the European Union briefly cast some doubt over the timing of the Company’s float, however this concern was unwarranted and the share issue was oversubscribed. Concepta is at the forefront of a huge growth market within consumer healthcare, and through its clear route to market and the potential for its technology, the investment case is clear to see.

hxxp://www.cambridgenetwork.co.uk/news/concepta-plc-the-mobile-health-company-that-defied-brexit-to9394/

[smart_investor] 10/8/2016 08:33

Good spot cottoner.

I have removed that until ADVFN can get it right.

[cottoner] 09/8/2016 21:03

Market Cap:

For anyone looking in and seeing ADVFN give a current MCAP of £29.6M with a share price of 12.75p.

This is incorrect, the actual MCAP is less than half of that.

CPT currently have 109,160,573 New Ordinary Shares in issue.

At 12.75p the correct MCAP is £13.9M.

[smart_investor] 08/8/2016 12:16

Yea big demand today! We are getting some nice media coverage which no doubt helps.

[jestercat2] 08/8/2016 11:22

Cripes - these are flying off the shelves today. Good luck all.

[smart_investor] 08/8/2016 07:13

New Article Published by ShareProphets

Buy Concepta at 12p and at up to 17.5p - target to sell 28p

Investment Case: The AIM admission of Concepta (CPT) a couple of weeks ago was through a reverse takeover of shellmeister (Adam Reynolds)-saved Frontier Resources International (FRI). We backed Reynolds when he became involved in Frontier, but despite his track-record, then was clearly somewhat speculative as we awaited a deal to be delivered. Now it has and it looks like Reynolds has delivered another promising one…

Operations: Concepta has developed a pioneering product, 'MyLotus', for home self-testing for women with unexplained infertility. The company notes this “is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'”. Additionally, it adds that “our proprietary platform lends itself to wider family home-health monitoring, and we believe there are exciting growth opportunities for Concepta in the future within the growing global connected healthcare sector”.

Management Incentive: CEO Erik Henau has more than 35 years of experience in life sciences companies (Amersham International, Oxoid) and consumer diagnostics (Unipath/Alere) and finished his career at Alere as International OTC Director. His annual salary is £105,000 and he has 213,333 shares (0.20%). Adam Reynolds is Non-Executive Chairman on £50,000 per annum and has 1,155,555 shares (1.06%). An Advisory Board includes Dr Ian Gilham and David Evans of Axis-Shield fame.

Financials: Results for its year-ended 31st January 2016 showed Concepta essentially remained a pre-revenue company and generating a loss of £1.1 million. However, a pro-forma balance sheet shows cash of more than £4 million and regulatory approvals for the 'My Lotus' product are now in place for launch in China, with roll out set to commence in the current quarter.

Risks: Having only been founded in 2013 and now just commencing revenue-generating operations, there is clear rate-of-adoption risk here. However, the company does look to have a superior product offering and a “first order from distributor with payment in advance expected after AIM admission”. There is also obvious risk in terms of operating in China, obtaining CE-Marking for UK and Europe in the anticipated approximately 9 months and the company’s anticipated further new product development. These are somewhat mitigated by an experienced management with a proven track record in the industry.

Valuation: The China roll out is expected to be followed by the UK and Europe in 2017 and the company notes “revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company”. At a current 12p offer price, the market cap here is £13 million. There clearly remains a speculative element, but near-term revenues, the market potential and the team here combine to see us tip the shares at a 12p offer with a limit buy price of 17.5p and initially targeting 28p to sell.

hxxp://www.shareprophets.com/views/22815/buy-concepta-at-12p-and-at-up-to-175p-target-to-sell-28p#sthash.6A7kTccQ.dpuf

[smart_investor] 08/8/2016 07:01

spoole5 - see my post number 41. If they can sell the product at that price then fantastic.

'The product, which will retail for £250-£300, has been developed for women who have been trying to conceive for six months or more.'